IEQ Capital’s Neurocrine Biosciences NBIX Stock Holding History

IEQ Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101M	Buy	765,982 +20,869	+3%	+$2.77M	0.47%	35
2025 Q4	$106M	Buy	745,113 +52,512	+8%	+$7.61M	0.32%	29
2025 Q3	$97.2M	Buy	692,601 +119,628	+21%	+$16.2M	0.3%	31
2025 Q2	$72M	Buy	572,973 +35,956	+7%	+$4.12M	0.44%	32
2025 Q1	$59.4M	Sell	537,017 -20,887	-4%	-$2.65M	0.47%	32
2024 Q4	$76.2M	Buy	557,904 +45,424	+9%	+$5.62M	0.74%	22
2024 Q3	$59M	Buy	512,480 +6,394	+1%	+$877K	0.72%	26
2024 Q2	$69.7M	Sell	506,086 -27	-0%	-$3.7K	0.94%	19
2024 Q1	$69.8M	Buy	506,113 +23,287	+5%	+$3.18M	1%	19
2023 Q4	$63.6M	Buy	482,826 +1,528	+0.3%	+$176K	1.06%	18
2023 Q3	$54.1M	Buy	481,298 +30	+0%	+$3.16K	1.1%	17
2023 Q2	$45.4M	Buy	+481,268	New	+$47M	0.92%	20

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IEQ Capital's NBIX Position: Q1 2026 in Review

IEQ Capital increased its Neurocrine Biosciences (NBIX) stake by 2.8% in Q1 2026, buying an estimated $2.77M and bringing the position to 765,982 shares worth $101M. The position accounts for 0.47% of the portfolio, ranked #35.

IEQ Capital first reported a position in NBIX in Q2 2023 and has held it in 12 quarters since. The position peaked at $106M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

IEQ Capital held 765,982 shares of Neurocrine Biosciences worth $101M as of Q1 2026.
IEQ Capital bought 20,869 Neurocrine Biosciences shares in Q1 2026, an estimated $2.77M.
Neurocrine Biosciences made up 0.47% of IEQ Capital's portfolio in Q1 2026, its #35 holding.
IEQ Capital first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 12 quarters since.
IEQ Capital's Neurocrine Biosciences position peaked at $106M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.